Obsidian Therapeutics (OBX) Q3 2026 earnings summary

Executive summary

• Amsoki-cel, an engineered autologous TIL therapy, is in Phase 2 for advanced melanoma and Phase 1 for NSCLC; no product sales revenue to date.

• Amsoki-cel showed a 67% ORR in 15 patients with ICI-resistant advanced melanoma; registration-enabling cohort enrollment is ongoing.

• Q3 net loss widened to $50.7M from $28.5M, including a one-time $15.1M acquired IPR&D charge following the Galera transaction.

• Quarter-end cash, cash equivalents and marketable securities totaled $324.4M after a $350M gross PIPE; planned operations are funded into H2 2028.